|
| Press Releases |
|
 |
|
| Friday, May 13, 2022 |
|
|
Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine |
| Hua Medicine (the "Company", stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin more info >> |
|
| Thursday, March 17, 2022 |
|
|
Hua Medicine Announces 2021 Annual Results |
| Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period"). The Reporting Period witnessed significant milestones in the commercialization process of dorzagliatin. more info >> |
|
| Sunday, September 26, 2021 |
|
|
Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin |
| Hua Medicine (2552.HK) announced that at the 6th China BioMed Innovation & Investment Conference (CBIIC), Professor Jianhua MA, Director, Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society, as one of the principal researchers presented the results from a clinical study called DREAM, which showed that dorzagliatin, a glucokinase activator and a first-in-class investigational drug of Hua Medicine, may make progress in diabetes remission. more info >> |
|
| Wednesday, September 15, 2021 |
|
|
Hua and Sinopharm Announced Supply Chain Strategic Cooperation |
| On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099). more info >> |
|
| Thursday, August 19, 2021 |
|
|
Hua Medicine Announces 2021 Interim Results |
| Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period"). more info >> |
|
| Friday, April 23, 2021 |
|
|
Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA) Globally |
| Hua Medicine (the "Company", Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type 2 Diabetes (T2D) was accepted by the China National Medical Products Administration (NMPA). more info >> |
|
| Friday, March 19, 2021 |
|
|
Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission |
| Hua Medicine (2552.HK), today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2020 (the "Reporting Period"). more info >> |
|
| Friday, December 18, 2020 |
|
|
Hua Medicine Completes Registration Phase III Trials; Announces 52-Week Result for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial |
| Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced: more info >> |
|
| Wednesday, October 14, 2020 |
|
|
Hua Medicine Announces the Drug Manufacturing Permit Granted for Dorzagliatin |
Hua Medicine (the "Company", Stock Code: 2552.HK) announces that, after review and on-site verification under the Marketing Authorization Holder ("MAH") system, the Company has obtained the drug manufacturing permit for dorzagliatin, its investigational first-in-class drug, issued by the Shanghai Municipal Drug Administrative Bureau.
more info >> |
|
| Monday, August 17, 2020 |
|
|
Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment dorzagliatin in China |
| Bayer and Hua Medicine, a leading innovative drug development company, today announced a commercialization agreement and strategic partnership for dorzagliatin, a novel diabetes treatment, in China. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Announcing Zion Shores
Apr 18, 2025 23:06 HKT/SGT
|
|
|
FXSpire Debuts in Dubai as Forex Traders Seek Smarter Tools Amid Global Uncertainty
Apr 18, 2025 21:00 HKT/SGT
|
|
|
FXiBot Launches with a Precision Strategy for GBP/USD Trading
Apr 18, 2025 20:00 HKT/SGT
|
|
|
Fujitsu Kozuchi AI technologies assist AKOS AI in delivering solutions for EU AI compliance
Apr 18, 2025 17:41 JST
|
|
|
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
Apr 18, 2025 16:52 JST
|
|
|
Hitachi Industrial Equipment Systems Launches Next-Generation Inverter System to Support Stable, Resilient Power Grids
Apr 18, 2025 16:46 JST
|
|
|
Thailand's Brewing Industry Gets a Boost with Life Below Labs' Local Yeast Hub
Apr 18, 2025 13:15 HKT/SGT
|
|
|
A Strategic Event for HR Leaders and Experts to Drive Transformation in the Saudi Workforce
Apr 18, 2025 10:22 HKT/SGT
|
|
|
PerfectSwell(R) Zion To Start Construction
Apr 17, 2025 19:00 HKT/SGT
|
|
|
OMP Positioned Highest for Ability to Execute in the 2025 Gartner(R) Magic Quadrant(TM) for Supply Chain Planning Solutions
Apr 17, 2025 17:00 HKT/SGT
|
|
|
Under the patronage of Maktoum bin Mohammed DIFC to host 3rd edition of Dubai FinTech Summit on 12-13 May 2025
Apr 17, 2025 15:26 HKT/SGT
|
|
|
MHIEC Receives Order from the Bureau of Sewerage of the Tokyo Metropolitan Government for Rebuilding of Sewage Sludge Incineration Facility
Apr 17, 2025 14:44 JST
|
|
|
Fiskl and Airwallex Transform SME Finance with AI 
Apr 17, 2025 12:30 HKT/SGT
|
|
|
Fujitsu collaboration with Supermicro and Nidec to reduce data center energy consumption
Apr 17, 2025 10:32 JST
|
|
|
CBL International Limited Reports 2024 Full-Year Results
Apr 17, 2025 09:17 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
